Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LHBETATAG mouse model

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 6, 2007, Pages 2476-2482

  Jockovich, Maria Elena ^a   Bajenaru, M Livia ^a   Piña, Yolanda ^a   Suarez, Fernando ^a   Feuer, William ^a   Fini, M Elizabeth ^a   Murray, Timothy G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANECORTAVE; ANGIOGENESIS INHIBITOR; COMBRETASTATIN A4; LUTEINIZING HORMONE BETA SUBUNIT; ACTIN; ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; COMBRETASTATIN; ENDOGLIN PROTEIN, MOUSE; KI 67 ANTIGEN; PREGNANE DERIVATIVE; SIGNAL PEPTIDE; STILBENE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG TARGETING; HISTOLOGY; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA BIPOLAR GANGLION CELL; RETINA TUMOR; RETINOBLASTOMA; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; DISEASE MODEL; FLUORESCENCE MICROSCOPY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERICYTE; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PREGNADIENEDIOLS; RETINAL NEOPLASMS; RETINOBLASTOMA; STILBENES; TUMOR MARKERS, BIOLOGICAL;

EID: 34347259576     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1397     Document Type: Article

References (36)

1. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States; 1974 through 1985. Arch Ophthalmol. 1990;108:128-132.
2. Pendergrass TW, Davis S. Incidence of retinoblastoma in the United States. Arch Ophthalmol. 1980;98:1204-1210.
3. Folkman J, Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol. 1976;16:207-248.
4. Burnier MN, McLean IW, Zimmerman LE, Rosenberg SH. Retinoblastoma: the relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci. 1990;31:2037-2040.
5. Tapper D, Langer R, Bellows AR, Folkman J. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery. 1979;86:36-40.
6. Albert DM, Tapper D, Robinson NL, Felman R. Retinoblastoma and angiogenesis activity. Retina. 1984;4:189-194.
7. Stitt AW, Simpson DA, Boocock C, Gardiner TA, Murphy GM, Archer DB. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intraocular tumours. J Pathol. 1998;186:306-312.
8. Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63:511-518.
9. Marback EF, Arias VE, Paranhos A Jr, Soares FA, Murphree AL, Erwenne CM. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol. 2003;87:1224-1228.
10. Kerimogglu H, Kiratli H, Dincturk AA, Soylemezoglu F, Bilgic S. Quantitative analysis of proliferation, apoptosis, and angiogenesis in retinoblastoma and their association with the clinicopathologic parameters. Jpn J Ophthalmol. 2003;47:565-571.
11. Rossler J, Dietrich T, Pavlakovic H, et al. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol. 2004;164:391-394.
12. Tong CT, Howard SA, Shah HR, et al. Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol. 2005;89:1217-1220.
13. Escalona-Benz E, Jockovich ME, Murray TG, et al. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2005;46:8-11.
14. Albert DM, Marcus DM, Gallo JP, O'Brien JM. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci. 1992;33:2354-2364.
15. Jockovich M-E, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LHBETATAG mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
16. Murray TG, O'Brien JM, Steeves RA, et al. Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol. 1996;114:1376-1381.
17. Scott IU, Murray TG, Feuer WJ, et al. External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol. 1999;117:766-770.
18. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
19. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol. 2002;22:5100-5113.
20. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, et al. Mcm2, Geminin, and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005;11:2510-2517.
21. Kumar P, Wang JM, Bernabeu C. CD 105 and angiogenesis. J Pathol. 1996;178:363-366.
22. Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J. 1987;19:225-234.
23. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest. 2003;112:1134-1136.
24. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncol. 2005;4:452-464.
25. Nehls V, Drenckhahn D. Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J Cell Biol. 1991;113:147-154.
26. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med. 1995;73:497-508.
27. Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: implications for anti-angiogenic tumour therapy. Angiogenesis. 2001;4:259-262.
28. Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH. Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann Neurol. 2005;57:119-127.
29. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61.
30. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
31. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;6:653-660.
32. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WMF. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol. 2003;162:183-193.
33. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-1393.
34. Vincent L, Kermani P, Young LM, et al., Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005;115:2992-3006.
35. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-1295.
36. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.